[D-Trp6]-LH-RH
![[D-Trp6]-LH-RH Structure](https://image.chemsrc.com/caspic/100/57773-63-4.png)
[D-Trp6]-LH-RH structure
|
Common Name | [D-Trp6]-LH-RH | ||
|---|---|---|---|---|
| CAS Number | 57773-63-4 | Molecular Weight | 1311.449 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C64H82N18O13 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.
Arch. Gynecol. Obstet. 287(3) , 447-53, (2013) To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.This prospective, non-randomized, self-controlled clinical trial included patients with rectovaginal endometr... |
|
|
Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
J. Clin. Oncol. 31(7) , 903-9, (2013) To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial.Patients age... |
|
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N. Engl. J. Med. 371(2) , 107-18, (2014) Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive ear... |
|
|
Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions.
J. Sex. Med. 10(2) , 570-8, (2013) Different clinical guidelines suggest using testosterone-lowering medications (TLM) in sex offender treatment in addition to psychotherapy. Within Germany, there are two officially approved agents. So far, no current data exist about the routine use of TLM in... |
|
|
Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Urol. Nurs. 33(5) , 236-44, 248, (2013) This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate ... |
|
|
Exemestane with ovarian suppression in premenopausal breast cancer.
N. Engl. J. Med. 371(14) , 1358, (2014)
|
|
|
Exemestane with ovarian suppression in premenopausal breast cancer.
N. Engl. J. Med. 371(14) , 1357, (2014)
|
|
|
Hormone therapy in premenopausal women with early-stage breast cancer.
N. Engl. J. Med. 371(2) , 175-6, (2014) Breast cancer is the most frequent cancer diagnosis in women worldwide and the most common cause of death from cancer. In the United States, 21% of breast cancers are diagnosed in women younger than 50 years of age, affecting almost 49,000 women, and this dis... |
|
|
Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
N. Engl. J. Med. 372(5) , 477-8, (2015) A fundamental feature of adjuvant therapy (treatment of apparently disease-free people to reduce the risk of recurrence) is that many are treated to benefit a few. The options for the adjuvant treatment of hormone-sensitive breast cancer have expanded in rece... |
|
|
Reply to Z. Blumenfeld et al.
J. Clin. Oncol. 31(29) , 3722-3, (2013)
|